| Froesch, Patrizia |
| Recruiting | 2 | 90 | Europe | Durvalumab, Radiotherapy | Swiss Group for Clinical Cancer Research | Non-small Cell Lung Cancer, NSCLC | 12/25 | 12/31 | | |
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
| Recruiting | 1/2 | 470 | Europe, Canada, Japan, US, RoW | NVL-655 | Nuvalent Inc., Nuvalent, Inc. | Locally Advanced Solid Tumor, Metastatic Solid Tumor | 02/26 | 03/26 | | |
salVage, NCT06114108: Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients |
|
|
| Recruiting | N/A | 128 | Europe | Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy), Systemic therapy, Surgery, Radiotherapy | Swiss Group for Clinical Cancer Research | Non-small Cell Lung Cancer (NSCLC), Stage IV | 11/27 | 11/27 | | |
| Guckenberger, Matthias |
DOSIS RCT, NCT02800551: Clinical Trial Comparing Dose-intensified SBRT With Conventional Radiation Therapy for Spinal Metastases |
|
|
| Active, not recruiting | 2 | 219 | Europe | dose-intensified image-guided SBRT using simultaneous integrated boost, External 3-dimensional conformal radiotherapy (3D-CRT) | University of Zurich | Spinal Metastasis | 01/23 | 07/24 | | |
| Recruiting | 2 | 90 | Europe | Durvalumab, Radiotherapy | Swiss Group for Clinical Cancer Research | Non-small Cell Lung Cancer, NSCLC | 12/25 | 12/31 | | |
| Recruiting | 2 | 92 | Europe | SBRT, oMRgRT, SOC chemotherapy | Ludwig-Maximilians - University of Munich, Heidelberg University, University of Zurich | Pancreatic Cancer | 12/23 | 05/24 | | |
AUSTRAL, NCT06680050: Phase II Study of Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen |
|
|
| Not yet recruiting | 2 | 21 | Europe | Durvalumab (MEDI4736), Ceralasertib, radiotherapy | Mario Negri Institute for Pharmacological Research | Non Small Cell Lung Cancer NSCLC | 01/27 | 01/28 | | |
| Terminated | 2 | 6 | Europe, RoW | Osimertinib, Tagrisso, Stereotactic Body Radiation Therapy (SBRT) | ETOP IBCSG Partners Foundation, AstraZeneca | NSCLC Stage IV, EGFR Gene Mutation | 10/23 | 02/24 | | |
| Recruiting | 2 | 96 | Europe | Durvalumab, Imfinzi, Carboplatin, Paclitaxel, Stereotactic body radiation therapy (SBRT), Surgical resection - definitive local treatment., Radical radiotherapy - definitive local treatment., Tremelimumab | ETOP IBCSG Partners Foundation, AstraZeneca | Non-small Cell Lung Cancer, Stage IV, Oligometastasis | 08/26 | 12/26 | | |
| Recruiting | N/A | 2000 | Europe, RoW | | European Organisation for Research and Treatment of Cancer - EORTC | Cancer | 04/26 | 04/26 | | |
SPRINT, NCT06462963: OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment |
|
|
| Not yet recruiting | N/A | 302 | NA | single-fraction SBRT, multiple-fraction SBRT | European Organisation for Research and Treatment of Cancer - EORTC | Breast Cancer, Prostate Cancer, NSCLC, Colorectal Cancer, Oligometastatic Disease | 11/28 | 11/28 | | |
HypoFocal SRT, NCT05746806: Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy |
|
|
| Recruiting | N/A | 36 | Europe | Ultrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy, Androgen deprivation therapy | Insel Gruppe AG, University Hospital Bern, University of Bern, Debiopharm International SA, Werner und Hedy Berger-Janser - Stiftung | Recurrent Prostate Cancer | 09/25 | 08/27 | | |
| Recruiting | N/A | 200 | Europe | Stereotactic body radiotherapy, SBRT, Palliative RT | European Organisation for Research and Treatment of Cancer - EORTC, Anticancer Fund, Belgium, Rising Tide Foundation | Gynecologic Cancer, Skin Cancer, Head and Neck Cancer, Sarcoma, Renal Cancer, Bladder Cancer, Upper Urinary Tract Carcinoma, Pancreatic Cancer, Hepatobiliary Cancer, Gastric Cancer, Small Bowel Cancer, Esophageal Cancer, Melanoma, Colon Cancer, Oligometastasis | 08/28 | 02/30 | | |
| Häfliger, Simon |
| Recruiting | 2 | 90 | Europe | Durvalumab, Radiotherapy | Swiss Group for Clinical Cancer Research | Non-small Cell Lung Cancer, NSCLC | 12/25 | 12/31 | | |
| Terminated | 1 | 12 | Europe | TLD-1, Talidox, Caelyx | Swiss Group for Clinical Cancer Research | Advanced Solid Tumors | 09/23 | 12/23 | | |
